Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: A comparison of parents and teachers as informants

Journal of Attention Disorders

Volumn 8, Issue 4, 2005, Pages 153-159

  Bohnstedt, Bradley N ^a   Kronenberger, William G ^a   Dunn, David W ^a   Giauque, Ann L ^a   Wood, Elisabeth A ^a   Rembusch, Mary E ^a   Lafata, Deborah ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADHD; Assessment; Atomoxetine; Attention; Hyperactivity

Indexed keywords

ATOMOXETINE; NORADRENALIN; PROPYLAMINE;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; OBSERVER VARIATION; PARENT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; UNIVERSITY;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOUBLE-BLIND METHOD; FACULTY; FEMALE; HUMANS; MALE; NOREPINEPHRINE; OBSERVER VARIATION; PARENTS; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES;

EID: 24944514288     PISSN: 10870547     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087054705278797     Document Type: Article

References (21)

1. Achenbach, T. M., McConaughy, S. H., & Howell, C. T. (1987). Child/adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specificity. Psychological Bulletin, 101, 213-232.
2. Allen, A. J., Thomason, C., Lambrect, L., Tamura, R., Tannock, R., Weiss, M., et al. (2005). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. Manuscript not submitted for publication.
3. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
4. Barkley, R. A. (1998). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (2nd ed.). New York: Guilford.
5. Biederman, J., Faraone, S. V., Monuteaux, M. C., & Grossbard, J. R. (2004). How informative are parent reports of attention-deficit/hyperactivity disorder symptoms for assessing outcome in clinical trials of long-acting treatments? A pooled analysis of parents' and teachers' reports. Pediatrics, 113, 1667-1671.
6. Birmaher, B., Axelson, D. A., Monk, K., Kalas, C., Clark, D. B., Ehmann, M., et al. (2003). Fluoxetine for the treatment of childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 415-423.
7. Cohen, J. (1992). A power primer. Psychological Bulletin, 112, 155-159.
8. Conners, C. K., & Barkley, R. A. (1985). Rating scales and checklists for child psychopharmacology. Psychopharmacology Bulletin, 21, 809-843.
9. DuPaul, G. J., Power, T. J., Anastopoulos, A. D., & Reid, R. (1998). ADHD Rating Scale-IV: Checklists, norms, and clinical interpretations. New York: Guilford.
10. Emslie, G. J., Heiligenstein, J. H., Wagner, K. D., Hoog, S. L., Ernest, D. E., Brown, E., et al. (2002). Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1205-1215.
11. Faraone, S. V., Biederman, J., & Roe, C. (2002). Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: A meta-analysis. Journal of Clinical Psychopharmacology, 22, 468-473.
12. Faries, D. E., Yalcin, I., Harder, D., & Heilgenstein, J. H. (2001). Validation of the ADHD Rating Scale as a clinician administered and scored instrument. Journal of Attention Disorders, 5, 107-115.
13. Findling, R. L., McNamara, N. K., Branicky, L. A., Schluchter, M. D., Lemon, E., & Blumer, J. L. (2000). A double-blind study of risperidone in the treatment of conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 509-516.
14. Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002). Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. Journal of Clinical Psychiatry, 63, 225-231.
15. Kaufman, J., Birmaher, B., Brent, D., Rao, U., Flynn, C., Moreci, P., et al. (1997). Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 980-988.
16. King, N. J., Tonge, B. J., & Mullen, P. M. (2000). Treating sexually abused children with posttraumatic stress symptoms: A randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 1347-1355.
17. Kratochvil, C. J., Heiligenstein, J. H., Dittmann, R., Spencer, T. J., Biederman, J., Wernicke, J., et al. (2002). Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 776-784.
18. Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., et al. (2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics, 108, E83.
19. The Multimodal Treatment of ADHD Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. Archives of General Psychiatry, 56, 1073-1086.
20. Pedhazur, E. J. (1982). Multiple regression in behavioral research (2nd ed.). New York: Holt, Rinehart & Winston.
21. Schachter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Canadian Medical Association Journal, 165, 1475-1488.